On Monday, Orchestra BioMed Holdings Inc (NASDAQ: OBIO) opened lower -6.71% from the last session, before settling in for the closing price of $2.98. Price fluctuations for OBIO have ranged from $2.37 to $8.87 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -273.68% over the last five years. Company’s average yearly earnings per share was noted -21.26% at the time writing. With a float of $26.75 million, this company’s outstanding shares have now reached $38.31 million.
The firm has a total of 70 workers. Let’s measure their productivity. In terms of profitability, gross margin is 92.58%, operating margin of -2383.89%, and the pretax margin is -2297.85%.
Orchestra BioMed Holdings Inc (OBIO) Insider Activity
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Orchestra BioMed Holdings Inc is 30.17%, while institutional ownership is 49.80%. The most recent insider transaction that took place on Jun 26 ’25, was worth 8,183. In this transaction Director of this company sold 2,683 shares at a rate of $3.05, taking the stock ownership to the 50,949 shares. Before that another transaction happened on Jun 26 ’25, when Company’s Director proposed sale 2,683 for $3.05, making the entire transaction worth $8,194.
Orchestra BioMed Holdings Inc (OBIO) Earnings and Forecasts
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.52 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -21.26% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 0.76% during the next five years compared to -273.68% drop over the previous five years of trading.
Orchestra BioMed Holdings Inc (NASDAQ: OBIO) Trading Performance Indicators
Check out the current performance indicators for Orchestra BioMed Holdings Inc (OBIO). In the past quarter, the stock posted a quick ratio of 3.34. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 36.85.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.77, a number that is poised to hit -0.50 in the next quarter and is forecasted to reach -1.77 in one year’s time.
Technical Analysis of Orchestra BioMed Holdings Inc (OBIO)
Analysing the last 5-days average volume posted by the [Orchestra BioMed Holdings Inc, OBIO], we can find that recorded value of 0.8 million was better than the volume posted last year of 0.29 million. As of the previous 9 days, the stock’s Stochastic %D was 18.79%.
During the past 100 days, Orchestra BioMed Holdings Inc’s (OBIO) raw stochastic average was set at 10.82%, which indicates a significant decrease from 12.12% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 76.70% in the past 14 days, which was lower than the 101.53% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $2.92, while its 200-day Moving Average is $4.49. Now, the first resistance to watch is $3.01. This is followed by the second major resistance level at $3.25. The third major resistance level sits at $3.41. If the price goes on to break the first support level at $2.61, it is likely to go to the next support level at $2.45. Should the price break the second support level, the third support level stands at $2.21.
Orchestra BioMed Holdings Inc (NASDAQ: OBIO) Key Stats
There are currently 38,313K shares outstanding in the company with a market cap of 106.51 million. Presently, the company’s annual sales total 2,640 K according to its annual income of -61,020 K. Last quarter, the company’s sales amounted to 870 K and its income totaled -18,760 K.
